Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Summary

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.

Timeline

Start

2024-10-23

Primary completion

2028-04-01

Completion

2028-08-01

Drugs

Indications